AR and neoplasm: Although 8β-VE2 showed potential as a general prostate cancer drug by decreasing cell survival and increasing tumor cell apoptosis in all cell variants (Figure 3), there is no just cause to replace approved first-line and next-generation ADT in androgen-sensitive prostate cancer or CRPC considering the effects we obtained on the pivotal target AR (Figure 2B).